{"groups":[{"description":"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"FG000","title":"Cohort A: Liposarcoma"},{"description":"21 days on and 7 days off\n\nPlacebo\n\nPlacebo: 21 days on and 7 days off","id":"FG001","title":"Cohort A: Liposarcoma, Placebo"},{"description":"Those patients who started on placebo and crossed over to active drug. Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"FG002","title":"Cohort A: Liposarcoma Crossover"},{"description":"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"FG003","title":"Cohort B: Osteosarcoma"},{"description":"21 days on and 7 days off\n\nPlacebo\n\nPlacebo: 21 days on and 7 days off","id":"FG004","title":"Cohort B: Osteosarcoma, Placebo"},{"description":"Patients who started on placebo and crossed over to active drug.\n\nAdults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"FG005","title":"Cohort B: Osteosarcoma Crossover"},{"description":"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"FG006","title":"Cohort C: Ewing Sarcoma"},{"description":"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"FG007","title":"Cohort D: Rhabdomyosarcoma"},{"description":"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"FG008","title":"Cohort E: Mesenchymal Chondrosarcoma"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"15"},{"groupId":"FG003","numSubjects":"22"},{"groupId":"FG004","numSubjects":"9"},{"groupId":"FG005","numSubjects":"11"},{"groupId":"FG006","numSubjects":"30"},{"groupId":"FG007","numSubjects":"10"},{"groupId":"FG008","numSubjects":"1"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"11"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"8"},{"groupId":"FG006","numSubjects":"22"},{"groupId":"FG007","numSubjects":"6"},{"groupId":"FG008","numSubjects":"1"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"11"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"8"},{"groupId":"FG007","numSubjects":"4"},{"groupId":"FG008","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Study enrollment ended early due to slow enrollment."}